Business Wire (Free subscription) | yesterday
CAMBRIDGE, Mass.--(BUSINESS WIRE)--ARIAD Pharmaceuticals, Inc. (Nasdaq: ARIA) today announced that the U.S. District Court for the District of Delaware granted ARIAD
World of stocks (Free subscription) | 03/10/2008
TheStreet.com Winners & Losers Financial Winners & Losers: Wachovia Tech Winners & Losers: Apple 10/3/2008 3:22 PM EDT Health Winners & Losers: Amgen, Mentor 10/3/2008 3:06 PM EDT Biotech Stock Mailbag: Curagen, Nuvelo 10/3/2008 5:25 PM EDT More News from TheStreet.com ETFs Small Business Investing A-Z Life and Money Moneymaking Strategies Report: Google, Yahoo! Delay Search Deal The two companies...
Fool.com (Free subscription) | 03/10/2008
The pharmaceutical fights off rival Roche.
The Street (Free subscription) | 03/10/2008
Amgen rises on an upheld court ruling regarding two anemia drugs. Mentor shares fall on UBS rating.
Business Wire (Free subscription) | 03/10/2008
THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Amgen (NASDAQ:AMGN) announced today that its Board of Directors has appointed François de Carbonnel to the Company's
Contract Pharma Breaking News (Free subscription) | 03/10/2008
A federal court granted Amgen a permanent injunction prohibiting Roche Holding AG from selling its Mircera anemia treatment in the U.S., as well as upheld a jury verdict regarding certain patent-infringement claims. Mircera is currently available in Europe and the FDA has approved the drug, but the legal dispute prevented its sale. The drug, if released in the U.S., would compete directly with Amgen's...
Medical News Today (Free subscription) | 03/10/2008
Amgen (NASDAQ:AMGN) announced today that the United States (U.S.) District Court in Boston issued its written decision upholding the prior jury verdict and court rulings regarding the infringement, validity and enforceability of 10 claims of four of Amgen's erythropoietin (EPO) patents.
Medical News Today (Free subscription) | 03/10/2008
Amgen Belgium announces the availability of Vectibix® (panitumumab), the first fully human anti-EGFR monoclonal antibody indicated as monotherapy for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) with non-mutated (wild-type)
Pharmalot (Free subscription) | 03/10/2008
A federal judge in Boston ruled the drugmaker infringed on Amgen’s patents with its Mircera anemia med, essentially upholding a preliminary decision issued in February. The order by US District Court Judge William Young deals a big setback to Roche, which already cut costs after its plans to market Mircera flopped and further underscores its [...]
Law Blog - WSJ.com (Free subscription) | 03/10/2008
Amgen Inc. said a federal court granted the biotechnology company a permanent injunction prohibiting Roche Holding AG from selling its Mircera anemia treatment in the U.S., while also upholding a jury verdict regarding certain patent-infringement claims.
24/7 Wall St. (Free subscription) | 02/10/2008
These are some of the top upgrades we are seeing from Wall Street analysts this morning: Amgen (AMGN) Raised to Outperform at William Blair. Capital Product... [[ This is a content summary only. Visit my website for full links, other content, and more! ]]
The Street (Free subscription) | 01/10/2008
Amgen's Aranesp and Johnson & Johnson's Procrit may increase the risk of death in cancer patients and lower overall survival.
PharmaGossip (Free subscription) | 01/10/2008
Europe's biotech sector is being hit hard by the credit crunch, with small and medium-sized companies being starved of funding from venture capitalists. As a result, Europe's dream to compete with the US biotech sector and create a heavyweight to rival Amgen or Genentech could be over, as increasing numbers of the continent's biotechs are bought out by big pharma. More at Pharmafocus
Red Orbit (Free subscription) | 01/10/2008
Amgen Inc., (NASDAQ: AMGN) announced it has received a summary of preliminary results from the Cochrane Collaboration's independent meta-analysis of patient-level data from previously conducted, randomized, controlled, clinical studies evaluating erythropoiesis-stimulating agents (ESAs) in cancer patients.
Sacramento Bee (Free subscription) | 29/09/2008
Andrew Messick, president of AEG Sports, which owns and operates the Amgen Tour of California, had a good day last Thursday. That's when Lance Armstrong announced he would be competing in the race. The Bee caught up with Messick by phone in Las Vegas, where he was attending Interbike, the major bicycle trade show.
